Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Recurrence × Anastrozole × Clear all

Phase

Status

Unknown 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 94 Neoplasms 6 Neoplasm Metastasis 6 Arthralgia 4 Advanced Breast Cancer 4 Carcinoma, Intraductal, Noninfiltrating 3 Osteoporosis 2 Multiple Endocrine Neoplasia Type 1 2 Breast Neoplasms, Male 2 Breast Carcinoma In Situ 2 Breast Cancer Metastatic 2 Triple Negative Breast Neoplasms 1 Sexual Dysfunction, Physiological 1 Seizures 1 Recurrence 1 Quality of Life 1 Pain 1 Obesity 1 Lethal Congenital Contracture Syndrome 2 1 Joint Diseases 1 Invasive Breast Cancer 1 Hypogonadism 1 Fractures, Bone 1 Erectile Dysfunction 1 Epilepsy 1 Bone Diseases, Metabolic 1 Bone Density 1 Advanced Metastatic Breast Cancer 1

Interventions

Cyclophosphamide 56 Dexamethasone 42 Lenalidomide 30 Peripheral Blood Stem Cell Transplantation 28 Rituximab 27 Filgrastim 25 Bortezomib 25 fludarabine phosphate 24 Carboplatin 22 Radiotherapy 21 Etoposide 21 Paclitaxel 19 Melphalan 19 Busulfan 18 Whole-Body Irradiation 17 Gemcitabine 17 Cytarabine 17 Cyclosporine 17 pomalidomide 16 Mycophenolic Acid 16 Bevacizumab 16 pembrolizumab 15 Cisplatin 15 fludarabine 14 Methotrexate 12 Calcium Dobesilate 12 venetoclax 11 Tacrolimus 11 Nivolumab 11 Bendamustine Hydrochloride 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00256698 2012-08-01

FACT

AstraZeneca

Phase 3 Completed

514 enrolled 13 charts

Breast Neoplasms, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡